Authors : Ram Mohan Jaiswal; Shweta Sharma; Naveen Gupta; Priyanka Soni; Sunil Polipalli; Prashanth Suravajhala; Manju Raghava

Volume/Issue : Volume 10 - 2025, Issue 7 - July

---

Google Scholar : https://tinyurl.com/36pkjr6e

Scribd : https://tinyurl.com/2fcnkc7r

DOI : https://doi.org/10.38124/ijisrt/25jul795

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

---

Abstract : We performed an integrative analysis of molecular profiles of 52 patients with Myeloid malignancies from a tertiary care teaching hospital in Jaipur. Targeted next-generation sequencing of 80 genes revealed 23 genes mutated in over 5% of patients. Mutational profiles differed considerably from previous studies. FLT3, DNMT, NPM1, N-RAS, ASXL1, CEBPA and RUNX1 mutations were more frequent in AML patients, while CBL, JAK2, GATA2, SF3B1, WT1, KRAS, MPL, TP53 and ZRSR2 were less frequent. Additionally, we identified ABL gene in 2 CML, DNMT in 1 MDS, and IDH1, JAK2, MPL, EZH2, PDGFRA in MPN/MPN-PV.

Keywords : Next-Generation Sequencing, Myeloid Plasma, Oncomine, Bioinformatics, Biomarkers.

References :

1. Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 Nov 24; 140(21):2228-2247. doi: 10.1182/blood.2022015853. 
2. Kahraman CY, Sincan G, Tatar A. Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian J Med. 2022 Jun; 54(2):181-185. doi: 10.5152/eurasianjmed.2022.21102. 
3. Levy MA, Santos S, Kerkhof J, Stuart A, Aref-Eshghi E, Guo F, et al. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies. Eur J Haematol. 2019;103:178–89.
4. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010 May 14;86(5):749-64. doi: 10.1016/j.ajhg.2010.04.006.
5. Mukherjee S, Sathanoori M, Ma Z, Andreatta M, Lennon PA, Wheeler SR, Prescott JL, Coldren C, Casey T, Rietz H, Fasig K, Woodford R, Hartley T, Spence D, Donnelan W, Berdeja J, Flinn I, Kozyr N, Bouzyk M, Correll M, Ho H, Kravtsov V, Tunnel D, Chandra P. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. Cancer Genet. 2017 Oct; 216-217:128-141. doi: 10.1016/j.cancergen.2017.07.010. Epub 2017 Aug 14.
6. Park J, Kim HS, Lee JM, Jung J, Kang D, Choi H, et al. Analytical and potential clinical performance of oncomine myeloid research assay for myeloid neoplasms. Mol Diagn Ther. 2020; 24: 579–92.
7. Schejbel L, Novotny GW, Breinholt MF, El Fassi D, Schöllkopf C, Hogdall E, Nørgaard P. Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis. Mol Diagn Ther. 2021 Mar;25(2):251-266. doi: 10.1007/s40291-021-00519-5.
8. Tran TB, Siddon AJ. Molecular findings in myeloid neoplasms. Int J Lab Hematol. 2023 Aug; 45(4):442-448. doi: 10.1111/ijlh.14118. 
9. Valent P, Valent PICUS. IDUS, CHIP and CCUS: diagnostic criteria, separation from MDS and clinical implications. Pathobiology. 2019; 86: 30–8.